CIK 0001088856 · Large accelerated filer
CORCEPT THERAPEUTICS INC
Sign in to watch- Ticker
- CORT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770487658
- Phone
- 650.688.8803
- Business address
- 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,067,988
- in 15 filings, $36.6M under 10b5-1 plans
Net −$41,067,988. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-30 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −4,200 | $105.54 | $443K | 91,930 |
| 2026-07-30 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −8,956 | $106.96 | $958K | 82,974 |
| 2026-07-30 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −400 | $108.46 | $43K | 82,574 |
| 2026-07-30 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −2,202 | $110.03 | $242K | 80,372 |
| 2026-07-30 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −600 | $110.95 | $67K | 79,772 |
| 2026-07-30 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −4,700 | $113.18 | $532K | 75,072 |
| 2026-07-30 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −15,477 | $114.96 | $1.8M | 59,595 |
| 2026-07-30 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −14,222 | $115.87 | $1.6M | 45,373 |
| 2026-07-30 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −7,089 | $116.96 | $829K | 38,284 |
| 2026-07-30 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −8,267 | $117.93 | $975K | 30,017 |
| 2026-07-30 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −4,783 | $118.73 | $568K | 25,234 |
| 2026-07-30 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −8,103 | $119.95 | $972K | 17,131 |
| 2026-07-30 | Mokari Atabak Chief Financial Officer | Sale 10b5-1 | −1,001 | $120.67 | $121K | 16,130 |
| 2026-07-30 | Mokari Atabak Chief Financial Officer | Option exercise · Stock option (right to buy) 10b5-1 | −80,000 | 95,833 | ||
| 2026-07-15 | WILSON JAMES N Director | Sale 10b5-1 | −1,079 | $86.78 | $94K | 1,093,464 |
| 2026-07-15 | WILSON JAMES N Director | Sale 10b5-1 | −3,969 | $87.74 | $348K | 1,089,495 |
| 2026-07-15 | WILSON JAMES N Director | Sale 10b5-1 | −2,974 | $88.81 | $264K | 1,086,521 |
| 2026-07-15 | WILSON JAMES N Director | Sale 10b5-1 | −1,978 | $89.49 | $177K | 1,084,543 |
| 2026-07-15 | Mokari Atabak Chief Financial Officer | Option exercise 10b5-1 | +15,833 | $19.26 | $305K | 31,963 |
| 2026-07-15 | Mokari Atabak Chief Financial Officer | Option exercise 10b5-1 | +24,167 | $23.06 | $557K | 56,130 |
Page 7 of 50 · 995 trades